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Primary aldosteronism (PA) is a common form of endocrine hypertension mainly caused by a 2 
unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). 3 
Autoantibodies that activate the angiotensin II type 1 receptor (AT1R-Abs) have been reported in 4 
patients with disorders associated with hypertension. Our objective was to assess AT1R-Ab levels 5 
in patients with PA (APA, n=40; BAH, n=40) relative to patients with primary hypertension (n=40), 6 
preeclampsia (n=23) and normotensive individuals (n=25). AT1R-Abs in whole sera were measured 7 
using 2 different ELISAs which gave contrasting results. A functional cell-based assay was used to 8 
quantify activation of the angiotensin II type 1 receptor (AT1R) using whole sera or affinity-purified 9 
antibodies in the absence or presence of losartan (a specific AT1R antagonist). Serum samples 10 
from all groups displayed different levels of AT1R activation with different responses to losartan. 11 
Patients with BAH displayed higher losartan-independent affinity-isolated agonistic AT1R-Ab levels 12 
compared with patients with APA (P<0.01) and with normotensive individuals (P<0.0001). In 13 
patients with APA, BAH and PH combined, higher aldosterone-to-renin ratios and lower plasma 14 
renin concentrations were associated with higher compared with lower agonistic AT1R-Abs levels. 15 
In patients with PA, higher AT1R-Ab activity was associated with an increased likelihood of a 16 
diagnosis of BAH compared with APA and with the presence of adrenal hyperplasia detected by 17 
computed tomography. Taken together these data suggest that agonistic AT1R-Abs may have a 18 
functional role in a subgroup of patients with primary aldosteronism.  19 
 3 
Introduction 20 
Primary aldosteronism (PA) is a form of endocrine hypertension caused by the overproduction of 21 
aldosterone from one or both adrenal glands (unilateral or bilateral PA, respectively). Unilateral PA 22 
is predominantly caused by an aldosterone-producing adenoma (APA) and bilateral forms by 23 
bilateral adrenocortical hyperplasia (BAH).1 APA and BAH mainly arise sporadically but uncommon 24 
familial forms have been described (familial hyperaldosteronism types I-IV).2,3 Substantial progress 25 
has been made in understanding the pathophysiology of familial PA and sporadic APAs with the 26 
identification of germline mutations causing 4 familial forms of hyperaldosteronism4-9 and somatic 27 
mutations which drive aldosterone excess in 50-80% of APAs.2,10-12 These advances, however, have 28 
not been replicated in understanding the pathogenesis of sporadic BAH. The bilateral nature of 29 
the disease led to the proposal of circulating factors, which could trigger bilateral chronic 30 
stimulation of the adrenal zona glomerulosa. 31 
 32 
Graves disease is an established example of an autoimmune disease caused by agonistic 33 
autoantibodies which activate the thyroid stimulating hormone receptor (TSHR) resulting in 34 
thyroid hormone production and thyroid cell proliferation.13-15 In addition to agonistic antibodies, 35 
antagonistic and neutral autoantibodies to the TSHR have been described which either block TSH 36 
activity or have no apparent effect.15 Autoimmune responses to other G protein coupled receptors 37 
have been reported in several studies implicating a role for autoantibody activation of the 38 
angiotensin II type 1 receptor (AT1R), the 1-adrenergic and 1-adrenergic receptors in several 39 
cardiovascular disorders.16-25 Furthermore, multiple studies have reported the detection of 40 
autoantibodies to the angiotensin II type 1 receptor (AT1R-Abs) in patients with preeclampsia.20,26 41 
AT1R-Abs which recognize the AFHYESQ peptide (position 165-171) in the second extracellular 42 
loop of the AT1R have been implicated as autoantibody-mediated drivers of AT1R agonism. 43 
 4 
Specifically, ELISAs employing an immobilized synthetic AFHYESQ peptide are often used to assay 44 
AT1R-Ab levels.20,27 Using either ELISA or functional assays, AT1R-Abs have also been reported in 45 
patients with PA in whom AT1R-Ab levels are variously reported as higher in patients with APA 46 
than with BAH, higher in BAH compared with APA or similar levels in both subtypes of PA.28-30 47 
These studies have either used ELISA-based assays, which do not provide information on the 48 
agonistic effect of AT1R-Abs, or have included only small cohorts of patients with PA. 49 
 50 
Our objective was to establish if functionally active AT1R-Abs are present in a large cohort of 80 51 
patients with PA (40 patients with APA, 40 with BAH) in comparison with primary hypertension 52 
(PH, n=40), preeclampsia (PE, n=23) and normotensive individuals (NT, n=25) using 3 assays: 2 53 
different ELISA-based assays both using immobilized full-length AT1R and a highly sensitive cell-54 
based AT1R activation functional assay.  55 
 56 
The data that support the findings of this study are available from the corresponding author upon 57 
reasonable request. 58 
Methods 59 
Patient samples 60 
For quantification of AT1R-Abs and AT1R activating activity, serum samples from 80 patients with 61 
PA (40 with APA and 40 with BAH), 40 with primary hypertension (PH), 23 women with 62 
preeclampsia (PE) and 25 normotensive blood donors (NT) were used. PA was diagnosed in 63 
accordance with the Endocrine Society guideline.31 Patients were screened for PA using the 64 
plasma aldosterone-to-direct renin concentration ratio and diagnosis was confirmed by the 65 
intravenous saline load test according to local criteria.32 All patients with confirmed PA underwent 66 
computed tomography (CT) scanning and adrenal venous sampling. The cut-off selectivity index to 67 
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determine success of catheterization was ≥ 2 and for the lateralization index to diagnose unilateral 68 
PA ≥ 4.32 PH was diagnosed in accordance with the ESH/cardiology guidelines33 after ruling out PA, 69 
pheochromocytoma and Cushing syndrome. PE and Graves disease were diagnosed as described 70 
previously.34,35 Blood sampling for patients with PA and PH was performed at screening for 71 
secondary hypertension. Whenever possible, patients were under no treatment or before the 72 
beginning of an anti-hypertensive therapy. When necessary blood pressure was controlled using 73 
the calcium channel blocker verapamil or the -blocker doxazosin, alone or in combination, in 74 
accordance with the ES guideline.31 Blood samples from patients with Graves disease were 75 
withdrawn at the first medical visit and from patients with PE in the third trimester. All 76 
participants gave written informed consent and the protocol was approved by the local ethics 77 
committee. 78 
 79 
AT1R autoantibody measurements 80 
All AT1R-Abs were measured using 3 different assays. Two commercially available ELISA kits were 81 
used to quantify autoantibodies against the recombinant human full-length AT1R (ELISA-Creative 82 
Diagnostics and ELISA-CellTrend).36, 37 The third assay was a cell based AT1R activation assay 83 
(Invitrogen Gene BLAzer beta-lactamase reporter system) to measure agonistic AT1R activity in 84 
total serum and in affinity-isolated IgG fractions after pre-incubation for 1 hour with vehicle or 100 85 
M losartan. Immunoglobulins (IgGs) were affinity isolated on protein A/G agarose from 1 mL 86 
patient serum and 1/10 of the affinity-isolated IgGs was used in the functional assay. The isolation 87 
of IgGs on protein A/G agarose and their depletion from serum samples was confirmed by 88 
Western blotting using a horseradish peroxidase conjugated goat anti-human antibody (Millipore, 89 
1:50000 dilution) (Figure S1).  90 
 91 
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The cell based AT1R activation assay employed AT1R-bla U2OS cells which stably express the AT1R 92 
linked at the C-terminus to the Gal4-VP16 transcription factor via a TEV (Tobacco Etch Virus) 93 
protease cleavage site (E-X-X-Y-X-Q-G/S) (Invitrogen). The U2OS cells also stably express TEV 94 
protease-tagged--arrestin/TEV and a -lactamase reporter gene with Gal4-responsive upstream 95 
activator sequences. Following AT1R activation, the TEV-protease--arrestin is recruited to the 96 
AT1R receptor C-terminus and cleaves the TEV cleavage sequence releasing GAL4-VP16 which 97 
activates expression of the -lactamase reporter gene. A Förster resonance energy transfer (FRET) 98 
substrate comprising coumarin and fluorescein fluorophores was used to measure reporter gene 99 
activity (ThermoFisher, LiveBLAzer-FRET B/G substrate). In the absence of -lactamase reporter 100 
gene expression, the FRET substrate is intact, coumarin excitation transfers fluorescence 101 
resonance energy to fluorescein resulting in emission of green fluorescence. When the substrate is 102 
cleaved, energy transfer is disrupted and a blue fluorescence signal is emitted from coumarin 103 
excitation.  Reporter activities, corresponding to AT1R activation, are given as response ratios 104 
which are the ratio of coumarin to fluorescein fluorescence signals (ratio of cleaved to uncleaved 105 
substrate) normalized for negative control wells (mock-treated cells). 106 
 107 
TSHR activation assay 108 
Activity of affinity-isolated IgGs from serum of Graves disease patients was measured using a TSHR 109 
agonistic cell-based assay to determine if autoantibody functional activity was maintained 110 
following the IgG isolation procedure. The assay uses TSHR ACTOne cells, a HEK-293 CNG (human 111 
embryonic kidney-293 cyclic nucleotide gated) cell line with overexpression of recombinant 112 
human TSHR (MyBiosource). The modified CNG channel opens in response to elevated 113 
intracellular cAMP levels and the resultant ion influx and membrane depolarization is measured 114 
with a fluorescent membrane potential dye. The assay measures intracellular cAMP levels as a 115 
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response ratio between TSHR ACTOne cells compared with the parental control cell line (HEK-293 116 
CNG cells).  117 
 118 
Adrenal morphology 119 
CT imaging was used to classify absence or presence of adrenal hyperplasia in adrenals with an 120 
abnormal morphology. The absence of hyperplasia group included adrenals with an adenoma but 121 
without hyperplasia, the presence of hyperplasia group included adrenals with hyperplasia alone 122 
or hyperplasia and an adenoma. Hyperplasia was defined as mean limb width ≥ 5 mm.38 Patients 123 
with no adrenal abnormality visible on CT images were excluded from the morphologic analysis. 124 
 125 
Statistical analyses 126 
Data were analyzed with the Kolmogorov-Smirnov and Shapiro-Wilk tests to determine 127 
distributions. Group differences were calculated for normally distributed data using the ANOVA 128 
and post-hoc Bonferroni tests. Non-normally distributed data were analyzed using the Kruskal-129 
Wallis test. Accordingly, data are expressed as mean ± SD or median (25th to 95th percentile). 130 
Categorical variables are presented as absolute numbers and percentages and differences were 131 
analyzed with a Chi-square test. Adjusted logistic regression analyses were performed to assess 132 
associations of AT1R-Abs and the diagnosis of BAH. IBM SPSS Statistics version 22.0 was used for 133 
all analyses.  134 
 135 
Results  136 
Clinical parameters of patients with primary aldosteronism versus primary hypertension 137 
Groups of patients with APA and BAH had the same age as patients with PH and a similar gender 138 
distribution with no significant differences in the proportion of males and females between APA, 139 
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BAH and PH groups (47.5-57.9%). There were no significant between-group differences in systolic 140 
or diastolic blood pressure at baseline or in body mass index in patients with APA, BAH and PH 141 
(Table 1). As expected, patients with APA or BAH had higher plasma aldosterone concentrations 142 
(PAC) and lower direct plasma renin concentrations (DRC) at baseline relative to the PH group 143 
(PAC: APA group, 569 [283-1071]; BAH, 416 [311-583]; PH 225 [128-394] pmol/L and DRC: APA 144 
group, 4.3 [2.0-11.2]; BAH, 3.4 [2.0-7.3]; PH, 18.2 [8.9-45.1] mU/L). Likewise, patients with APA 145 
had lower serum potassium concentrations compared with patients with BAH and PH (APA group, 146 
2.9 [2.6-3.2]; BAH, 3.3 [3.0-3.7]; PH 3.9 [3.6-4.2] mmol/L) (Table 1). 147 
 148 
ELISA quantification of AT1R-Abs in different groups  149 
Autoantibodies recognizing epitopes on the full-length human recombinant AT1R in serum from 150 
patients with APA, BAH, PH, PE and NT were measured using 2 different ELISAs. Using one 151 
approach (ELISA-Creative Diagnostics), patients with PE displayed significantly higher AT1R-Ab 152 
levels compared with all other groups (P<0.0001 for all comparisons). The titer of AT1R-Abs was 153 
highly similar in the APA and BAH groups (APA group, [0.06-0.21]; BAH, 0.12 [0.06-0.26] ng/mL) 154 
with no differences observed compared with either the PH or NT groups (PH group, 0.15 [0.10-155 
0.25]; NT, 0.11 [0.01-0.19] ng/mL) (Figure, panel A; Table S1). We also used a second ELISA (ELISA-156 
CellTrend) based on AT1R-Ab binding to the full-length AT1R in its native conformation.36, 37 157 
Patients with APA and BAH displayed highly similar levels of AT1R-Abs (APA group, 14.2 [10.4-158 
22.0]; BAH, 14.1 [10.1-19.7] U/mL) which were not significantly different from the PH or NT groups 159 
(PH group, 13.5 [10.7-18.7]; NT, 11.4 [10.6-20.8] ng/mL) (Figure, panel B, Table S1). However, 160 
AT1R-Ab levels were significantly lower in patients with PE (8.7 [6.9-11.6] ng/mL) compared with 161 
all other groups (P<0.05 for all comparisons).  162 
 163 
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Quantification of AT1R agonistic activity in serum samples from different groups 164 
We tested if serum from the different subgroups of patients and individuals could activate the 165 
AT1R in a cell based functional assay. Treatment of cells with angiotensin II (0-500 pM) 166 
demonstrated a dose-dependent effect on AT1R activation which was ablated by pre-incubation of 167 
the cells for 1 h with the AT1R antagonist losartan (100 M). The assay measured a specific AT1R 168 
functional response to 50 pM angiotensin II which was significantly higher than a corresponding 169 
incubation in the presence of losartan (P<0.05) (Figure S2). Higher AT1R agonistic activity was 170 
measured in serum samples from all groups (P<0.001 for absence versus presence of losartan for 171 
each group). There were no between-group differences for AT1R agonist activity in the absence of 172 
losartan. However, in the presence of losartan there were overall differences in the measured 173 
functional activation of the AT1R (P<0.001) with the BAH group showing higher activity compared 174 
with the APA (P=0.001), PE (P<0.0001) and NT groups (P<0.0001). The PH group also displayed 175 
higher levels of functional AT1R-Abs relative to the NT (P<0.0001) and the PE groups (P=0.001) 176 
(Figure, panel C, Table S1). 177 
 178 
Affinity isolation of IgG fractions from different groups of serum samples 179 
To determine if the losartan-independent AT1R activating activity in serum samples was due to 180 
IgGs or to other circulating factors, such as angiotensin II, IgGs were affinity-isolated from all 181 
serum samples on protein A/G-agarose to assess AT1R agonist activity in the cell based AT1R 182 
functional assay (Figure S1, Figure S2). We first tested if the IgG affinity-isolation procedure 183 
produced functionally active autoantibodies. For this, IgGs were isolated from the serum of 184 
patients with Graves disease (N=9) and measured TSHR activation using a cell based functional 185 
assay. Using IgG fractions isolated from patients with Graves disease, comparison of TSHR 186 
activation in the ACT-ONE cell line (with stable overexpression of the human TSHR) with the 187 
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parental cell line (without expression of recombinant human TSHR) demonstrated that 6 of the 9 188 
IgG fractions displayed TSHR agonistic activity (Figure S3). The remaining 3 IgG fractions exhibited 189 
no significant TSHR activation indicating neutral or blocking activity to the TSHR (Figure S3). 190 
Overall, the approach used for the affinity isolation of autoantibodies from patients with Graves 191 
disease maintained TSHR agonist functional activity thereby validating the method used for the 192 
isolation of IgG fractions.  193 
 194 
Quantification of AT1R agonistic activity in affinity-isolated IgG fractions from different groups 195 
There were group differences in the cell-based assay response (overall difference P<0.001) using 196 
affinity-isolated IgGs. The BAH, PH and PE groups displayed higher levels of AT1R activating 197 
autoantibodies compared with the NT group (P<0.0001, P=0.007 and P<0.0001, respectively) and 198 
the BAH group had higher functional AT1R-Ab levels than the APA group (P=0.01). The agonistic 199 
AT1R-Ab levels were not abolished in the presence of losartan and significant group differences 200 
were observed (Table S1). Higher losartan-independent AT1R functional activity was measured with 201 
IgGs isolated from patients with BAH, PH and PE compared with the NT group (P<0.0001, P=0.006 202 
and P=0.016, respectively) and in the BAH versus APA groups (P=0.01) (Figure, panel D, Table S1). 203 
Comparison of AT1R activation in the cell assay with the functional response obtained with 204 
angiotensin II in the dose-response assay indicated that the median AT1R activation achieved with 205 
affinity-isolated antibodies from patients with BAH in the presence or absence of losartan was 206 
equivalent to 50 to 100 pM angiotensin II (Figure S2, Table S1).  207 
 208 
Clinical parameters of patients according to functional AT1R-Ab levels 209 
Affinity-purified agonistic AT1R-Ab levels were categorized into higher and lower AT1R-Ab levels 210 
according to the median AT1R-Ab activity in the cell-based assay for patients with APA, BAH and 211 
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PH combined. In this cohort, in the absence of losartan, patients with BAH had higher AT1R-Ab 212 
levels (BAH represented 41.2% of 68 patients of the combined cohort with higher AT1R-Ab levels 213 
compared with 23.1% of 52 patients with lower AT1R-Ab levels, P=0.037) (Table 2). Patients with 214 
APA had lower AT1R-Ab levels (APA represented 23.5% of 68 patients of the combined cohort with 215 
higher AT1R-Ab levels compared with 46.2% of 52 patients with lower AT1R-Ab levels, P=0.009) 216 
(Table 2). Although functional AT1R-Ab levels were similar in the BAH versus PH groups (Figure, 217 
panel D; Table S1), patients with PH with lower versus higher AT1R-Ab levels were similarly 218 
distributed in the combined cohort (APA + BAH + PH). The PH group with lower AT1R-Ab levels 219 
comprised 30.7% of 52 patients of the combined cohort compared with 35.3% of 68 patients with 220 
higher levels (P=0.603) (Table 2). 221 
 222 
In the APA, BAH and PH combined cohort, higher levels of agonistic AT1R-Abs were also associated 223 
with a higher aldosterone-to-renin ratio (ARR_DRC) and a lower direct renin concentration (DRC) 224 
in the absence of losartan (DRC: 5.7 mU/mL [2.2-27.0] versus 11.7 mU/mL [5.7-31.8], P=0.011; 225 
ARR_DRC: 47 [13-139] versus 23 [10-55], P=0.029, for higher versus lower AT1R-Ab levels, 226 
respectively) and these differences were maintained in the presence of losartan (Table 2).  227 
 228 
Patients with PA with higher agonistic AT1R-Ab levels, in the absence of losartan, had an increased 229 
likelihood of a diagnosis of BAH versus APA after adjustment for confounding effects of age, 230 
systolic BP, PAC or DRC (Table 3). Higher losartan-independent agonistic AT1R-Ab levels were not 231 
associated with a diagnosis of BAH compared with APA after correction for systolic BP and PAC. 232 
There was no association of higher AT1R-Ab levels with a diagnosis of BAH compared with PH in 233 
either the absence of presence of losartan (Table 3).  234 
 235 
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Adrenal morphology according to functional AT1R-Ab levels 236 
Adrenal abnormalities were absent on CT images in 3 patients diagnosed with APA and in 17 237 
patients diagnosed with BAH, and these cases were excluded from the morphologic analysis. 238 
Higher affinity-purified AT1R-Ab levels in the absence of losartan were associated with the 239 
presence of adrenal hyperplasia when AT1R-Ab levels were treated as either a continuous variable 240 
(AT1R activating activity response ratio, 0.3 [0.26-0.39] versus 0.26 [0.23-0.29] in the presence and 241 
absence of hyperplasia, respectively, P=0.011) or categorized as higher or lower according to the 242 
median AT1R-Ab level (76.0 % of 25 patients with adrenal hyperplasia had higher AT1R-Ab levels 243 
compared with 37.1% of 35 patients without adrenal hyperplasia, P=0.003) (Table 4). In the 244 
presence of losartan, AT1R-Ab activities were similar in the presence versus absence of 245 
hyperplasia groups (Table 4).  246 
 247 
The distribution of individual patients with PA (APA and BAH) with adrenal hyperplasia according 248 
to AT1R-Ab activating activity is shown in Figure, panel D. In patients with PA, 83.3% of 12 and 249 
69.2% of 13 patients of patients classified with adrenal hyperplasia in the APA and BAH groups, 250 
respectively, had AT1R-Ab levels above or equal to the median value for their group in the 251 
absence of losartan (Figure, panel D).  252 
 253 
Discussion 254 
Autoantibodies that potentially elicit a functional response by binding to G protein-coupled 255 
receptors have been described in several cardiovascular disorders.25 Many studies have reported 256 
AT1R-Ab binding to an epitope in the second extracellular loop (AFHYESQ) of the AT1R in different 257 
groups of patients.20 The best characterized is AT1R-Abs in PE where a functional role has been 258 
implicated using cardiomyocyte contraction assays in which assay response was ablated either by 259 
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the AT1R antagonist losartan or with the AFHYESQ peptide.20,39 The prevalence of AT1R-Abs in PE 260 
varies widely with reports employing an ELISA ranging from 48% of 58 patients40 to 100% of 25 261 
patients.20 However, targeting the AFHYESQ peptide in ELISA assays has limitations because 262 
binding to linear immobilized peptides may not correlate with AT1R agonism and binding to 263 
conformational epitopes cannot be assessed.41 A commercially available ELISA (ELISA-CellTrend), 264 
routinely used in solid organ transplantation, has been developed based on autoantibody binding 265 
to the full-length AT1R in the native conformation.37 Using this conformation sensitive assay, we 266 
demonstrated highly contrasting low AT1R-Ab levels compared with a different ELISA method 267 
which appears to greatly overestimate the level of AT1R-Abs in patients with preeclampsia. 268 
 269 
The pathophysiology of sporadic BAH is poorly understood. Advances in knowledge are hampered 270 
by the highly limited availability of tissue samples for molecular studies because patients with BAH 271 
are not usually surgically-treated. Despite this, recent studies have suggested a role for 272 
adrenocortical hyperplasia in patients with bilateral but asymmetrical inappropriate aldosterone 273 
production42 or a role for small clusters of cells located beneath the adrenal capsule with high 274 
aldosterone synthase expression (called aldosterone-producing cell clusters) in surgically-treated 275 
patients diagnosed with bilateral PA.43 Thus, BAH may not be a distinct entity but a disorder 276 
comprising clinical and biochemical variability arising from morphological heterogeneity 277 
representing the variable response of the adrenal cortex to circulating, environmental and genetic 278 
factors.  279 
 280 
A role for autoantibodies that trigger bilateral chronic stimulation of the adrenal zona glomerulosa 281 
via activation of the AT1R has been proposed44 but a pathogenic role for AT1R-Abs in PA remains 282 
unclear because of conflicting reports that used different methods for assessment of antibody 283 
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levels.28-30 One study found a 2-fold increase of AT1R-Abs against the AFHYESQ peptide in an ELISA 284 
in patients with APA (n=26) compared with patients with BAH (n=20) and proposed the use of this 285 
assay as a potential diagnostic tool to differentiate the two different types of PA.28 Using a similar 286 
ELISA-based AFHYESQ assay no difference in AT1R-Ab levels were observed in 44 patients with PA 287 
(15 with APA, 29 with BAH) compared with 18 normotensive individuals (n=18) and no difference 288 
in AT1R-Ab levels between the patients with APA and BAH.30 However, measuring antibody 289 
binding to the linear AFHYESQ peptide in ELISA assays, as used in many studies, does not 290 
necessarily correlate with AT1R agonism.  291 
 292 
To address the agonistic activity of AT1R-Abs in PA, Kem et al29 reported increased AT1R-Ab levels 293 
in patients with PA (n=13) compared with control subjects (n=20) using cell-based assays to 294 
measure a functional response in AT1R-transfected cells and reported the contractile effects of 295 
the isolated IgGs in perfused rat cremaster arterioles. In contrast to other reports, an increased 296 
prevalence of AT1R-Abs in patients with BAH relative to patients with APA was reported.29 297 
However, the number of patients with PA assessed for AT1R-Ab levels was small, the stimulating 298 
activity of low potency and the affinity-isolated antibodies did not elicit a dose-dependent 299 
functional effect.29   300 
 301 
The diverse observations for the prevalence and potential role of AT1R-Abs and the limited 302 
understanding of the pathogenesis of bilateral PA highlight the need for studies to measure 303 
autoantibodies using robust functional assays in large and well characterized cohorts of patients 304 
with PA. Herein, we assessed AT1R-Ab levels in a cohort of 80 patients with PA diagnosed in 305 
accordance with rigorous criteria and with subtype diagnosis (APA versus BAH) defined by adrenal 306 
venous sampling. Following this approach, ELISA-based measurements using the immobilized full-307 
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length AT1R gave contrasting results for AT1R-Ab levels in patients with PE and did not reveal 308 
statistical differences between patients with BAH or APA compared with PH or NT. We hence also 309 
used a cell-based AT1R functional assay which exploits specific activation of the -lactamase 310 
reporter gene upon ligand binding to the AT1R. With this assay, similar levels of AT1R activation 311 
were measured in whole serum from all groups. However, between-group differences were shown 312 
using affinity-isolated IgGs which demonstrated significantly higher levels of agonistic AT1R-Abs in 313 
patients with BAH compared with APA and in patients with BAH, PH and PE relative to the NT 314 
group both in the presence and absence of losartan.  315 
 316 
These activities implicate the existence of an alternative epitope structurally remote from losartan 317 
binding sites. AT1R is increasingly recognized as a multi-ligand binding surface and epitopes 318 
discovered in solid organ transplant patients are not identical with those in patients with PE37. 319 
Some reports suggest that, in addition to classical G protein-mediated signaling, “biased” AT1R 320 
signaling mediated by -arrestin45,46 may play a role in aldosterone production and have 321 
pathological implications for the progression to heart failure after myocardial infarction.47,48 322 
Because losartan antagonizes G protein signaling but is ineffective in ablating -arrestin-mediated 323 
signaling,47,48 the losartan-independent activity we report presumably comprises “biased” AT1R 324 
signaling. 325 
 326 
We also demonstrate that higher agonistic AT1R-Ab levels are associated with clinical parameters 327 
characteristic of autonomous aldosterone production in PA such as higher aldosterone-to-renin 328 
ratios and lower plasma renin levels. The degree of functional activity of AT1R-Abs in this study 329 
appears low but is potentially pathologically relevant because the median AT1R-Ab agonistic 330 
activity in patients with BAH corresponds to greater than that achieved with 50 pM angiotensin II, 331 
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a concentration similar to plasma angiotensin II concentrations reported in patients with chronic 332 
kidney disease and considerably higher than in healthy individuals.49 333 
 334 
A potential pathogenic role of agonistic AT1R-Abs in PA is suggested by the association of higher 335 
active AT1R-Ab levels - in the absence but not in the presence of losartan - with an increased 336 
likelihood of a diagnosis of BAH compared with APA and with an increased incidence of adrenal 337 
hyperplasia. Adrenals harboring an APA also often display focal or diffuse cortical hyperplasia 338 
adjacent to the adenoma.42,50 It is notable that within the group of patients with APA, those with 339 
evidence of hyperplasia at CT scanning tend to display higher levels of AT1R-Ab agonistic activity 340 
compared with patients with APA without hyperplasia. The imaging data should however be 341 
treated with caution considering the potential for incorrect classification of an adenoma versus 342 
hyperplasia.    343 
 344 
Taken together the present data indicate that AT1R-Abs may play a role in patients with BAH 345 
which could feasibly exacerbate the effects of additional pathophysiological factors such as 346 
aldosterone-producing cell clusters which have been reported as larger, more numerous and with 347 
a higher prevalence of aldosterone-driver mutations than normal adrenals.43 Notwithstanding the 348 
observations reported herein, the possibility that AT1R-Abs are a marker of hypertension rather 349 
than having a pathogenic role cannot be excluded. 350 
 351 
In conclusion, some patients with disorders related to hypertension have activating 352 
autoantibodies to the AT1R. Some AT1R-Abs function via a mechanism diverse from the classical G 353 
protein-mediated AT1R signaling and implicate a role for losartan-independent “biased” AT1R 354 
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signaling. Overall, the present study suggests a role for agonistic autoantibodies to the AT1R in a 355 
subgroup of patients with PA, comprising those patients with adrenal hyperplasia,  356 
  357 
Perspectives  358 
A role for AT1R-Abs has been implicated in several cardiovascular disorders but evidence for a 359 
direct function in disease pathophysiology is lacking. In vivo experiments in mice subjected to 360 
infusion of AT1R-Abs from patients with PA could clarify the impact of AT1R-Abs on aldosterone 361 
production. A longitudinal analysis is planned to measure the response of AT1R-Ab levels to 362 
adrenal surgery or mineralocorticoid receptor antagonism in patients with PA with long term 363 
follow up. Epitope mapping using synthetic peptides to competitively abolish autoantibody-364 
mediated AT1R activation will aid the identification of AT1R-Ab binding sites and establish any role 365 
for autoantibodies in “biased” signaling.  366 
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Novelty and Significance 
What is New? 
 AT1R-Ab levels were measured in groups of patients with hypertension compared with 
normotensive individuals  
 Higher agonistic AT1R-Abs levels were present in bilateral primary aldosteronism, primary 
hypertension and preeclampsia groups compared with normotensive individuals 
 Patients with bilateral versus unilateral primary aldosteronism had higher levels of 
agonistic AT1R-Abs  
What is relevant? 
 AT1R-Abs measured by ELISA did not correlate with functional activation of the AT1R 
 Patients with higher AT1R-Ab activity levels have an increased likelihood of a diagnosis of 
bilateral than unilateral primary aldosteronism 
 Higher levels of agonistic AT1R-Abs were associated with higher aldosterone-to-renin 
ratios and lower plasma renin concentrations 




Agonistic autoantibodies to the AT1R are present in patients with disorders related to 
hypertension and may contribute to autonomous aldosterone production and adrenal hyperplasia 





Figure. Measurement of AT1R autoantibodies and AT1R activating response in patients with 
primary aldosteronism, primary hypertension, preeclampsia and in normotensive individuals 
 
Scatter dot plots showing quantification of AT1R-Ab in total serum of patients with PA (APA and BAH), PH, PE and 
normotensive individuals by measurements using ELISA-Creative Diagnostics (Panel A) or ELISA-CellTrend (Panel B). A 
cell-based AT1R activation assay was used to measure AT1R-Ab agonist activity in total serum (Panel C) or in agarose-
A/G affinity isolated IgG fractions (Panel D) in the absence (light grey points) or presence (dark grey points) of 100 
m losartan as indicated. Panel D also highlights the agonistic AT1R-Ab levels in patients with adrenal hyperplasia at 
CT imaging (red points). The response ratio represents AT1R-activation of -lactamase activity  measured as coumarin 
to fluorescein fluorescence (cleaved to uncleaved substrate ratio) normalized for negative controls. Horizontal lines 
within boxes indicate the median, and the lower and upper horizonal lines indicate the 95% CI. P values were 
calculated using the Kruskal-Wallis test and indicate **** difference (P<0.0001) from NT (Panel A); * difference 
(P<0.05) from NT (Panel B); *** difference (P<0.001) absence versus presence of losartan for each subgroup; $ 
difference (P<0.01) from BAH; #### difference (P<0.0001) from NT (presence of losartan); ++++ difference (P<0.0001) 
from PE (presence of losartan); ++ difference (P<0.01) from PE (presence of losartan); (Panel C); ** difference (P<0.01) 
from NT (absence of losartan), **** difference (P<0.0001) from NT (absence of losartan); $ difference (P<0.01) 
(presence of losartan); #### difference (P<0.0001) from NT (presence of losartan); ## difference (P<0.01) from NT 
(presence of losartan); # difference (P<0.05) from NT (presence of losartan); (Panel D). Numbers of patient samples in 
each subgroup were APA, N=40; BAH, N=40; PH, N=40; PE, N=23; NT, N=25. APA, aldosterone-producing adenoma; 
AT1R-Ab, angiotensin II type 1 receptor autoantibodies; BAH, bilateral adrenal hyperplasia; PH, primary hypertension; 













APA vs BAH APA vs PH BAH vs PH  
Age (years) 52  10.2 52  9.7 52  19.9 0.964 N.A. N.A. N.A. 
Sex (ref. male) 21 (52.5%) 19 (47.5%) 16 (42.1%) 0.656 N.A. N.A. N.A. 
BMI (Kg/m2) 27.3  4.1 26.2  5.0 27.4  6.0 0.500 N.A. N.A. N.A. 
Systolic BP (mmHg) 151  21.5 151  23.8 156  17.2 0.461 N.A. N.A. N.A. 
Diastolic BP (mmHg) 93  11.0 95  13.6 91  14.6 0.469 N.A. N.A. N.A. 
PAC (pmol/L) 569 [283-1071] 416 [311-583] 225 [128-394] < 0.001 0.742 < 0.001 0.002 
DRC (mU/L) 4.3 [2.0-11.2] 3.4 [2.0-7.3] 18.2 [8.9-45.1] < 0.001 0.831 < 0.001 < 0.001 
ARR_DRC 108 [36-306] 114 [71-162] 16 [6-26] < 0.001 1.000 < 0.001 < 0.001 
Lowest serum K+ 
(mmol/L) 
2.9 [2.6-3.2] 3.3 [3.0-3.7] 3.9 [3.6-4.2] < 0.001 0.001 < 0.001 < 0.001 
 
Table 1. Clinical parameters of patients with primary aldosteronism and primary hypertension 
Clinical data of patients with PA (APA or BAH) and PH are presented as average values ± SD, absolute numbers with proportions in parenthesis (%) or as medians with lower 
and upper quartiles in parentheses. P values designate the presence of group differences by the ANOVA and Bonferroni post-hoc tests (age, BMI, systolic and diastolic BP), 
Kruskal–Wallis test (PAC, DRC, ARR_DRC and potassium), or Chi square test (sex). Numbers of patient samples in each subgroup are indicated. APA, aldosterone-producing 
adenoma; ARR_DRC, aldosterone-to-renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, blood pressure; DRC, direct 





AT1R-Ab level minus losartan  
P-value 
AT1R-Ab level plus losartan 
P-value 



















Age (years) 54  14.8 55  16.6  0.749 54  15.5 55  16.2 0.851 
Sex (ref. male) 30 (57.7) 39 (57.4) 0.970 28 (49.1) 41 (65.1) 0.077 
BMI (Kg/m2) 28.2  4.7 27.5  5.0 0.431 27.2  4.2 28.4  5.3 0.177 
Systolic BP (mmHg) 151  23.9 147  19.2 0.376 148  25.1 149  17.4 0.709 
Diastolic BP (mmHg) 92  15.0 86  12.5 0.018 89  16.9 89  10.7 0.854 
PAC (pmol/L) 235 [150-553] 300 [167-556] 0.499 236 [130-550] 286 [186-569] 0.338 
DRC (mU/L) 11.7 [5.7-31.8] 5.7 [2.2-27.0] 0.011 11.9 [5.3-39.7] 5.6 [2.3-16.3] 0.003 
ARR_DRC 23 [10-55] 47 [13-139] 0.029 19 [7-60] 49 [16-137] 0.003 
Lowest serum K+ 
(mmol/L) 




Table 2. Clinical parameters of patients with primary aldosteronism and primary hypertension according to functional AT1R-Ab levels 
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Clinical parameters of the combined cohort of patients with APA, BAH and PH were analyzed according to AT1R-Ab levels (affinity-purified autoantibody activity measured with 
the cell-based assay) categorized according to the median value of the combined cohort (median values, 0.27 and 0.28 in the absence and presence of losartan respectively). 
Data are presented as average values ± SD, absolute numbers with proportions in parenthesis (%) or as medians with lower and upper quartiles in parentheses. P values 
designate the presence of group differences by the ANOVA and Bonferroni post-hoc tests (age, BMI, systolic and diastolic BP), Kruskal–Wallis test (PAC, DRC, ARR_DRC and 
potassium), or Chi square test (sex, diagnosis). Numbers of patient samples in each subgroup are indicated. APA, aldosterone-producing adenoma; ARR_DRC, aldosterone-to-
renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, blood pressure; DRC, direct renin concentration; PAC, plasma 





BAH vs. APA BAH vs. PH 
OR (CI 95%) P-value OR (CI 95%) P-value 
Agonistic AT1R-Ab level - losartan     
AT1R-Abs (ref. ≥ median) 3.425 (1.342-8.696) 0.010 1.515 (0.589-3.891) 0.388 
Age (years) 0.976 (0.941-1.012) 0.186 1.025 (0.997-1.053) 0.078 
AT1R-Abs (ref. ≥ median) 3.663 (1.420-9.434) 0.007 1.495 (0.587-8.817) 0.339 
Systolic BP (mmHg) 1.019 (0.005-1.044) 0.116 0.993 (0.972-1.015) 0.532 
AT1R-Abs (ref. ≥ median) 3.521 (1.361-9.091) 0.009 1.887 (0.688-5.319) 0.231 
PAC (pmol/L) 1.001 (1.000-1.003) 0.072 1.003 (1.001-1.005) 0.003 
AT1R-Abs (ref. ≥ median) 3.546 (1.395-9.009) 0.008 1.603 (0.630-4.065) 0.322 
DRC (mU/L) 0.996 (0.989-1.004) 0.298 0.996 (0.990-1.002) 0.221 
Agonistic AT1R-Ab level + losartan     
AT1R-Abs (ref. ≥ median) 2.571 (1.027-6.452) 0.044 1.980 (0.786-5.000) 0.147 
Age (years) 0.973 (0.938-1.009) 0.135 1.026 (0.999-1.055) 0.062 
AT1R-Abs (ref. ≥ median) 2.358 (0.943-5.882) 0.066 1.832 (0.745-4.505) 0.187 
Systolic BP (mmHg) 1.015 (0.992-1.039) 0.211 0.993 (0.971-1.014) 0.497 
AT1R-Abs (ref. ≥ median) 2.381 (0.947-5.988) 0.065 2.278 (0.838-6.211) 0.107 
PAC (pmol/L) 1.001 (1.000-1.002) 0.086 1.003 (1.001-1.005) 0.003 
AT1R activation (ref. ≥ median) 2.500 (1.007-6.211) 0.048 1.698 (0.678-4.255) 0.258 
DRC (mU/L) 0.966 (0.989-1.004) 0.323 0.997 (0.990-1.003) 0.314 
 
Table 3. Association of agonistic affinity-purified AT1R-Ab levels and diagnosis of BAH  
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Logistic regression analyses were performed to determine the potential association of agonistic autoantibody levels with a diagnosis of BAH with adjustment for confounding 
effects of a single clinical variable per level (age, systolic BP, PAC or DRC) in the absence and presence of losartan. Autoantibody levels were categorized according to the 
median affinity-purified AT1R-Ab level in the cell-based assay as shown. Data are presented as odds ratios (OR) with 95% confidence intervals (CI). An OR > 1 indicates an 
increased likelihood for a diagnosis of BAH in the presence of agonistic AT1R-Ab activity ≥ median value independent of the tested confounding variable (age, systolic BP, PAC, 
DRC). APA, aldosterone-producing adenoma; AT1R, angiotensin II type 1 receptor; BAH, bilateral adrenal hyperplasia; BP, blood pressure; DRC, direct renin concentration; PAC, 

















Agonistic AT1R-Ab level - losartan    
AT1R-Abs (response ratio) 0.26 [0.23-0.29] 0.30 [0.26-0.39] 0.011 
AT1R-Abs (ref. ≥ median) 13 (37.1) 19 (76.0) 0.003 
Agonistic AT1R-Ab level + losartan    
AT1R-Abs (response ratio) 0.27 [0.20-0.30] 0.30 [0.24-0.36] 0.149 
AT1R-Abs (ref. ≥ median) 16 (45.7) 15 (60.0) 0.205 
 
Table 4. Functional AT1R autoantibody levels stratified by adrenal morphology  
Adrenal morphology of patients with PA was determined from CT results to classify absence or presence of 
hyperplasia in adrenals with morphologic abnormalities. Numbers of patient samples in each subgroup are indicated. 
Affinity-purified agonistic AT1R-Ab levels, measured with the cell-based assay, were treated as continuous variables 
and presented as medians with lower and upper quartiles in parenthesis or categorized as higher and lower agonistic 
AT1R-Ab levels according to the median value for patients with APA and BAH combined and presented as absolute 
numbers with proportions in parenthesis. P values designate the presence of group differences by the Kruskal–Wallis 
test (AT1R-Ab levels), or Chi square test (diagnosis, AT1R-Ab levels after categorization).  
 
